glp-1 alternatives Drugs from the Gray Market Tired of GLP-1s? Comparing Gastric
Description
This often decides whether a case qualifies under federal product liability standards
Key Takeaways of the GLP-1 Receptor Agonist Market Based on drug class, the liraglutide segment is projected to dominate, holding a share of 26.5% in 2026
Koehler JA, Baggio LL, Yusta B, et al
However, additional research is needed on this possible association
The weight loss is thought to be caused by slowing digestion by increasing the time it takes for food to leave the body
